All Stories

  1. A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study
  2. Riesgo de recurrencia tras retirada de la anticoagulación en pacientes con enfermedad tromboembólica venosa no provocada: validación externa del nomograma de Viena y del modelo predictivo DASH
  3. Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
  4. El dilema de la reducción de tratamiento en pacientes con asma moderado-grave controlados
  5. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
  6. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry
  7. Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin
  8. Extended treatment of cancer-associated thrombosis
  9. D‐dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry
  10. Natural history of patients with venous thromboembolism and hereditary hemorrhagic telangiectasia. Findings from the RIETE registry
  11. Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study
  12. Correction to: Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  13. Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE Database
  14. Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism
  15. Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis
  16. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease
  17. Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry
  18. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis
  19. Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'
  20. D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
  21. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
  22. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry
  23. Towards a precision medicine in venous thromboembolism associated to lung cancer
  24. Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos
  25. Management appropriateness and outcomes of patients with acute pulmonary embolism
  26. Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism
  27. Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism
  28. Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy
  29. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism
  30. Prevalence of dual clarithromycin and metronidazole resistance in Helicobacter pylori estimated by molecular methods in Santiago, Chile
  31. Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score
  32. Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
  33. Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
  34. Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista
  35. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism
  36. Sex Differences in Patients With Occult Cancer After Venous Thromboembolism
  37. Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up
  38. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis
  39. Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism
  40. Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation
  41. Response
  42. The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site
  43. Development of a Risk Prediction Score for Occult Cancer in Patients With VTE
  44. Calidad de vida en pacientes diagnosticados de embolia de pulmón aguda sintomática
  45. Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry
  46. Noninvasive ventilation during the weaning process in chronically critically ill patients
  47. Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrothic
  48. Search predictive factors of recurrence in venous thromboembolic disease associated with cancer after withdrawal of the anticoagulation. HISPALIS study
  49. Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate
  50. Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study
  51. DVT Management and Outcome Trends, 2001 to 2014
  52. Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units
  53. Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001–2013)
  54. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective
  55. Trends in the Management and Outcomes of Acute Pulmonary Embolism
  56. Discharge Planning of Neuromuscular Patients with Noninvasive Mechanical Ventilation After Difficult Weaning from Invasive Mechanical Ventilation: From ICU to Home Care
  57. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry
  58. High correlation between 2 flow cytometry platforms in the microparticles analysis using a new calibrated beads strategy
  59. Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
  60. Respiratory intermediate care units: Noninvasive ventilation for severe acidotic patients
  61. Factors associated with mortality and survival in venous thromboembolism and hidden or concurrent cancer
  62. Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients
  63. The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism
  64. Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism
  65. Corrigendum to ‘Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients’ [Thrombosis Research 134 (2014) 617–621]
  66. A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis
  67. Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy
  68. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity
  69. Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism
  70. Venous thromboembolism in patients immobilised at home
  71. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate
  72. Fondaparinux in the initial and long-term treatment of venous thromboembolism
  73. Gender differences in cancer patients with acute venous thromboembolism
  74. Lights and shadows of non-invasive mechanical ventilation for chronic obstructive pulmonary disease (COPD) exacerbations
  75. A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs
  76. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy
  77. Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
  78. Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism
  79. C0211: Prevalence of Metabolic Syndrome and All-Causes Mortality in Patients with Acute Symptomatic Venous Thromboembolism (VTE)
  80. C0246: Quality of Life in Acute Symptomatic Pulmonary Embolism and Low-Risk Prognosis
  81. C0306: Rivaroxaban for Treatment of Venous Thromboembolism. A Real-Life Perspective in 103 Patients
  82. D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer
  83. Pulmonary Embolism and Concomitant Paradoxical Embolism. A Case Report
  84. Tromboembolismo pulmonar y embolia paradójica concomitante. A propósito de un caso
  85. Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar
  86. La escala predictiva de Khorana en pacientes con enfermedad tromboembólica venosa y cáncer
  87. Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática
  88. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism
  89. Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular
  90. Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism
  91. Hipertensión pulmonar tromboembólica crónica
  92. Clinical Manifestations of Sarcoidosis
  93. Platelet count and outcome in patients with acute venous thromboembolism
  94. Análisis de 3 métodos para determinar el dímero D en pacientes con sospecha de trombosis venosa profunda
  95. Control ambulatorio de los pacientes con trombosis venosa profunda y cáncer: estudio de seguridad, costes e impacto presupuestario
  96. Chronic Thromboembolic Pulmonary Hypertension Due to Upper-Extremity Deep Vein Thrombosis Caused Thoracic Outlet Syndrome
  97. Hipertensión pulmonar tromboembólica crónica debida a trombosis venosa profunda de miembro superior por síndrome del desfiladero torácico
  98. Updated Guidelines for the Treatment of Pulmonary Sarcoidosis
  99. Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis
  100. Malformaciones de la vena cava inferior como causa de trombosis venosa profunda. A propósito de dos casos
  101. Dyslipidemia as a long-term marker for survival in pulmonary embolism
  102. Lung cancer mortality in Spain: estimating the future burden to the year 2028
  103. Gender differences in lung cancer mortality trends in Andalusia 1975–2008: a joinpoint regression analysis
  104. Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism
  105. Right Atrium Mass in a 28-Year-Old Patient with Pulmonary Embolism Taking Contraceptives
  106. Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia
  107. Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up survey
  108. Hallazgos en el lavado broncoalveolar de pacientes con enfermedad pulmonar intersticial difusa. Estudio de una cohorte prospectiva de 562 pacientes
  109. Hemorragia pulmonar por capilaritis pauciinmunitaria aislada con anticuerpos anticitoplasma de los neutrófilos negativos
  110. Síndrome hepatopulmonar en pacientes con hepatopatía avanzada: estudio de 24 casos
  111. Infección por Aspergillus terreus en pacientes con EPOC en tratamiento con corticoides. A propósito de tres casos
  112. Hemorragia digestiva baja asociada a celecoxib